Cover Image
市場調查報告書

美國的分子診斷市場:檢查數量預測及企業

United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test (Blood Screening, Food Pathogen, Tissue Typing HLA)

出版商 Renub Research 商品編碼 300967
出版日期 內容資訊 英文 146 Pages; 87 Figures; 4 Tables
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的分子診斷市場:檢查數量預測及企業 United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test (Blood Screening, Food Pathogen, Tissue Typing HLA)
出版日期: 2017年08月28日 內容資訊: 英文 146 Pages; 87 Figures; 4 Tables
簡介

分子診斷是急速進化的領域,新的技術和應用領域不斷追加。分子診斷從目前以症狀和代理標記的使用為基礎的病情診斷,換成基因和蛋白質體學分析的診斷,是有潛力的領域。美國的分子診斷市場至2018年將擴大到目前的二倍以上。

本報告提供美國的分子診斷市場相關調查、市場概要和數量、各方面應用的預測、各企業趨勢、市場課題等彙整資料,為您概述為以下內容。

第1章 摘要整理

第2章 美國的分子診斷市場:檢查數量與預測

  • 市場及預測
  • 檢查數量及預測

第3章 美國的分子診斷市場及數量市場佔有率

第4章 美國的分子診斷市場及預測:各方面應用

  • 癌症檢驗
    • 乳癌
    • 大腸癌
    • 前列腺癌
    • 其他
  • 傳染病檢查
    • 病毒檢驗
    • 人類乳突病毒(HPV)檢驗
    • HAI檢驗
    • 重症加護檢驗
  • 遺傳基因檢驗市場
  • 血液篩檢市場
  • 食品病原菌檢驗市場
  • 組織型決策(HLA)檢驗市場

第5章 美國的分子診斷檢查數量:各方面應用

  • 癌症檢驗
  • 傳染病檢查
  • 遺傳基因檢驗市場

第6章 美國的分子診斷市場:各企業

  • Roche
  • Abbott Laboratories
  • Myriad Genetics
  • Biomerieux
  • Qiagen
  • Hologic Inc.
  • Becton Dickinson
  • Siemens
  • Cepheid

第7章 促進要素

第8章 課題

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

As the evolution of innovative technologies is happening in the field of research and medicine, molecular diagnostics is growing rapidly. United States molecular diagnostics market is projected to surpass US$ 9 billion by 2024. Molecular diagnostics system is one of the hopeful systems that enable automation of extraction of high-quality nucleic acids from a wide variety of sample types and the selection of targeted, individualized treatment options. Molecular diagnostics system offers early disease detection, potentially before symptoms have even occurred.

In this report United States molecular diagnostics market has been segmented into three major categories: Oncology Test, Infectious Disease Test and Genetic Disease Test. Further, Oncology Test has been segmented into four major categories: Breast Cancer Test, Colorectal Cancer Test, Prostate Cancer Test and Other Cancer Test. Infectious Disease Test has been segmented into four major categories, namely, Virology, HAI, HPV and Critical Care Test and Genetic Test has been segmented into Blood Screening, HLA and Food Pathogen Test.

United State Molecular Diagnostics Market Shares: Overview

Our study found that both the Oncology and Infectious Test market have significant market in United States Molecular Diagnostics Market. In Molecular Oncology Test market; Breast cancer dominates the market on the other side in Molecular Infectious Test market; Virology is leading all other segments. While in terms of Tests Volume; Genetics test is leading all way ahead from Infectious and Oncology Test owing to Food Pathogen Test Volume.

The top players in United States Molecular Diagnostics Market includes several familiar names such as Roche, Hologic, Becton Dickinson, Myraid Genetics, Qiagen and Abbott, Siemens, bioMérieux and Cepheid.

Renub Research study titled “United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast Cancer, Colorectal Cancer, Prostate Cancer, Others) Infectious Diseases (Virology Test, HPV Test, HAI Test, Critical Care Test) Genetic Test (Blood Screening, Food Pathogen Test, Tissue Typing HLA Test)&rldquo; provides a comprehensive assessment of the fast-evolving, high-growth United States Molecular Diagnostics Market. This is the 2nd edition of the report published by Renub Research.

This 146 page report with 87 Figures and 4 Tables studies the United States Molecular Diagnostics from 4 view points:

  • 1) Molecular Diagnostics Market and Forecast
  • 2) Segments Market & Forecast
  • 3) Segments Test Volume & Forecast
  • 4) Company Molecular Diagnostics Sales & Forecast

United States Molecular Diagnostics Market & Test Volume - Application Segment Analysis (2010 - 2024)

1. Oncology Test

  • a) Breast Cancer
  • b) Colorectal Cancer
  • c) Prostate Cancer
  • d) Others

2. Infectious Diseases

  • a) Virology Test
  • b) HPV Test
  • c) HAI Test
  • d) Critical Care Test

3. Genetic Test

  • a) Blood Screening
  • b) Food Pathogen Test
  • c) Tissue Typing (HLA Test)

Company Sales Analysis (2010 - 2024)

  • 1. Roche
  • 2. Abbott
  • 3. Myriad Genetics
  • 4. BioMerieux
  • 5. Qiagen
  • 6. Hologic Inc.
  • 7. Becton Dickinson
  • 8. Siemens
  • 9. Cepheid
  • 10. Others

Table of Contents

1. Executive Summary

2. United States Molecular Diagnostics Market & Forecast

3. United States Molecular Diagnostics Test Volume & Forecast

4. United States Molecular Diagnostics Market Share (2010-2024)

  • 4.1. Market Share & Forecast-(Oncology, Infectious, Genetics) Tests
  • 4.2. Segments Market Share & Forecast-(Breast, Colorectal, Prostate, Other) Cancer, (Virology, HAI, HPV, Critical Care, HLA, Blood Screening, Food Pathogen) Test
  • 4.3. Company Market Share-(Roche, Abbott, Myriad Genetics, BioMerieux, Qiagen, Hologic Inc., Becton Dickinson, Siemens, Cepheid, Others)

5. United States Molecular Diagnostics Test Volume Share (2010-2024)

  • 5.1. Volume Share & Forecast-(Oncology, Infectious, Genetics) Tests

6. Segments-United States Molecular Diagnostics Market (2010-2024)

  • 6.1. Oncology Test Market Share
  • 6.2. Oncology Test Market
    • 6.2.1. Breast Cancer Testing Market
    • 6.2.2. Colorectal Cancer Test Market
    • 6.2.3. Prostate Cancer Test Market
    • 6.2.4. Other Cancer Test Market
  • 6.3. Market Share-Infectious Disease Test
  • 6.4. Infectious Disease Test Market
    • 6.4.1. Virology Test Market
    • 6.4.2. HPV Test Market
    • 6.4.3. HAI Test Market
    • 6.4.4. Critical Care Test Market
  • 6.5. Genetic Test Market Share
  • 6.6. Genetic Test Market
    • 6.6.1. Blood Screening Market
    • 6.6.2. Food Pathogen Test Market
    • 6.6.3. Tissue Typing (HLA) Test Market

7. Segments-United States Molecular Diagnostics Test Volume (2010-2024)

  • 7.1. Oncology Test Volume Share
  • 7.2. Oncology Test Volume
    • 7.2.1. Breast Cancer Test Volume
    • 7.2.2. Colorectal Cancer Test Volume
    • 7.2.3. Prostate Cancer Test Volume
    • 7.2.4. Other Cancer Test Volume
  • 7.3. Infectious Disease Test Volume Share
  • 7.4. Infectious Disease Test Volume
    • 7.4.1. Virology Test Volume
    • 7.4.2. HPV Test Volume
    • 7.4.3. HAI Test Volume
    • 7.4.4. Critical Care Test Volume
  • 7.5. Genetic Test Volume Share
  • 7.6. Genetic Testing Test Volume
    • 7.6.1. Blood Screening Test Volume
    • 7.6.2. Food Pathogen Test Volume
    • 7.6.3. HLA Test Volume

8. Company-United States Molecular Diagnostics Sales & Forecast

  • 8.1. Roche
  • 8.2. Abbott Laboratories
  • 8.3. Myriad Genetics
  • 8.4. BioMerieux
  • 8.5. Qiagen
  • 8.6. Hologic Inc. (Acquired Gen-Probe)
  • 8.7. Becton Dickinson
  • 8.8. Siemens
  • 8.9. Cepheid
  • 8.10. Others

9. Growth Factors

  • 9.1. Growing Automation
  • 9.2. Rising Investment in Genomics & Proteomics Research
  • 9.3. Personalized Medicine Fuels Molecular Diagnostics

10. Challenges

  • 10.1. Regulatory Issues
  • 10.2. Reimbursement Capabilities
  • 10.3. Quality Checkpoints, Awareness & Acceptance

List of Figures

  • Figure 2-1: United States - Molecular Diagnostics Market (Million US$), 2010 - 2016
  • Figure 2-2: United States - Forecast for Molecular Diagnostics Market (Million US$), 2017 - 2024
  • Figure 2-3: United States - Molecular Diagnostics Test Volume (Million), 2010 - 2016
  • Figure 2-4: United States - Forecast for Molecular Diagnostics Test Volume (Million), 2017 - 2024
  • Figure 3-1: United States Molecular Diagnostics Market Share (Percent), 2010 - 2016
  • Figure 3-2: United States - Forecast for Molecular Diagnostics Market Share (Percent), 2017 - 2024
  • Figure 3-3: United States Molecular Diagnostics Test Volume Share (Percent), 2010 - 2016
  • Figure 3-4: United States - Forecast for Molecular Diagnostics Test Volume Share (Percent), 2017 - 2024
  • Figure 3-5: United States - Company Wise Molecular Diagnostics Market Share (Percent), 2010 - 2016
  • Figure 3-6: United States - Forecast for Company Wise Molecular Diagnostics Market Share (Percent), 2017 - 2024
  • Figure 4-1: United States - Molecular Diagnostic Oncology Testing Market (Million US$), 2010 - 2016
  • Figure 4-2: United States - Forecast for Molecular Diagnostic Oncology Testing Market (Million US$), 2017 - 2024
  • Figure 4-3: United States - Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2004 - 2016
  • Figure 4-4: United States - Forecast for Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2017 - 2024
  • Figure 4-5: United States - Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2010 - 2016
  • Figure 4-6: United States - Forecast for Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2017 - 2024
  • Figure 4-7: United States - Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2004 - 2016
  • Figure 4-8: United States - Forecast for Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2017 - 2024
  • Figure 4-9: United States - Other Molecular Diagnostic Cancer Testing Market (Million US$), 2004 - 2016
  • Figure 4-10: United States - Forecast for Other Molecular Diagnostic Cancer Testing Market (Million US$), 2017 - 2024
  • Figure 4-11: United States - Infectious Disease Testing Market (Million US$), 2010 - 2016
  • Figure 4-12: United States - Forecast for Infectious Disease Testing Market (Million US$), 2017 - 2024
  • Figure 4-13: United States - Virology Testing Market (Million US$), 2010 - 2016
  • Figure 4-14: United States - Forecast for Virology Testing Market (Million US$), 2017 - 2024
  • Figure 4-15: United States - HPV Testing Market (Million US$), 2010 - 2016
  • Figure 4-16: United States - Forecast for HPV Testing Market (Million US$), 2017 - 2024
  • Figure 4-17: United States - HAI Testing Market (Million US$), 2010 - 2016
  • Figure 4-18: United States - Forecast for HAI Testing Market (Million US$), 2017 - 2024
  • Figure 4-19: United States - Critical Care Testing Market (Million US$), 2010 - 2016
  • Figure 4-20: United States - Forecast for Critical Care Testing Market (Million US$), 2017 - 2024
  • Figure 4-21: United States - Genetic Testing Market (Million US$), 2010 - 2016
  • Figure 4-22: United States - Forecast for Genetic Testing Market (Million US$), 2017 - 2024
  • Figure 4-23: United States - Blood Screening Market (Million US$), 2006 - 2016
  • Figure 4-24: United States - Forecast for Blood Screening Market (Million US$), 2017 - 2024
  • Figure 4-25: United States - Food Pathogen Testing Market (Million US$), 2010 - 2016
  • Figure 4-26: United States - Forecast for Food Pathogen Testing Market (Million US$), 2017 - 2024
  • Figure 4-27: United States - HLA Testing Market (Million US$), 2008 - 2016
  • Figure 4-28: United States - Forecast for HLA Testing Market (Million US$), 2017 - 2024
  • Figure 5-1: United States - Oncology Test Volume (Million), 2010 - 2016
  • Figure 5-2: United States - Forecast for Oncology Test Volume (Million), 2017 - 2024
  • Figure 5-3: United States - Breast Cancer Test Volume (Million), 2004 - 2016
  • Figure 5-4: United States - Forecast for Breast Cancer Test Volume (Million), 2017 - 2024
  • Figure 5-5: United States - Colorectal Cancer Test Volume (Million), 2010 - 2016
  • Figure 5-6: United States - Forecast for Colorectal Cancer Test Volume (Million), 2017 - 2024
  • Figure 5-7: United States - Prostate Cancer Test Volume (Million), 2004 - 2016
  • Figure 5-8: United States - Forecast for Prostate Cancer Test Volume (Million), 2017 - 2024
  • Figure 5-9: United States - Other Cancer Test Volume (Million), 2004 - 2016
  • Figure 5-10: United States - Forecast for Other Cancer Test Volume (Million), 2017 - 2024
  • Figure 5-11: United States - Infectious Disease Test Volume (Million), 2010 - 2016
  • Figure 5-12: United States - Forecast for Infectious Disease Test Volume (Million), 2017 - 2024
  • Figure 5-13: United States - Virology Test Volume (Million), 2010 - 2016
  • Figure 5-14: United States - Forecast for Virology Test Volume (Million), 2017 - 2024
  • Figure 5-15: United States - HPV Test Volume (Million), 2010 - 2016
  • Figure 5-16: United States - Forecast for HPV Test Volume (Million), 2017 - 2024
  • Figure 5-17: United States - HAI Test Volume (Million), 2010 - 2016
  • Figure 5-18: United States - Forecast for HAI Test Volume (Million), 2017 - 2024
  • Figure 5-19: United States - Critical Care Test Volume (Million), 2010 - 2016
  • Figure 5-20: United States - Forecast for Critical Care Test Volume (Million), 2017 - 2024
  • Figure 5-21: United States - Genetic Testing Test Volume (Million), 2010 - 2016
  • Figure 5-22: United States - Forecast for Genetic Testing Test Volume (Million), 2017 - 2024
  • Figure 5-23: United States - Blood Screening Test Volume (Million), 2006 - 2016
  • Figure 5-24: United States - Forecast for Blood Screening Test Volume (Million), 2017 - 2024
  • Figure 5-25: United States - Food Pathogen Test Volume (Million), 2010 - 2016
  • Figure 5-26: United States - Forecast for Food Pathogen Test Volume (Million), 2017 - 2024
  • Figure 5-27: United States - HLA Test Volume (Million), 2008 - 2016
  • Figure 5-28: United States - Forecast for HLA Test Volume (Million), 2017 - 2024
  • Figure 6-1: Roche - United States Molecular Diagnostic Sales (Million US$), 2008 - 2016
  • Figure 6-2: Roche - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-3: Abbott Laboratories - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-4: Abbott Laboratories - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-5: Myriad Genetics - United States Molecular Diagnostic Sales (Million US$), 2007 - 2016
  • Figure 6-6: Myriad Genetics - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-7: Biomerieux - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-8: Biomerieux - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-9: Qiagen - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-10: Qiagen - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-11: Hologic-Gen-Probe - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-12: Hologic-Gen-Probe - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-13: Becton Dickinson - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-14: Becton Dickinson - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-15: Siemens - United States Molecular Diagnostic Sales (Million US$), 2008 - 2016
  • Figure 6-16: Siemens - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-17: Cepheid - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-18: Cepheid - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 6-19: Others - United States Molecular Diagnostic Sales (Million US$), 2010 - 2016
  • Figure 6-20: Others - Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 - 2024
  • Figure 7-1: United States - Investment in the Human Genome Project (Billion US$), 2003, 2012

List of Tables

  • Table 3-1: United States - Molecular Diagnostics Application Market Share (Percent), 2010 - 2016
  • Table 3-2: United States - Forecast for Molecular Diagnostics Application Market Share (Percent), 2017 - 2024
  • Table 3-3: United States - Molecular Diagnostics Application Test Volume Share (Percent), 2010 - 2016
  • Table 3-4: United States - Forecast for Molecular Diagnostics Application Test Volume Share (Percent), 2017 - 2024
Back to Top